Share

March 03, 2015; 84 (9) Article

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

Ludwig Kappos, Matthias Mehling, Rafael Arroyo, Guillermo Izquierdo, Krzysztof Selmaj, Valentina Curovic-Perisic, Astrid Keil, Mahendra Bijarnia, Arun Singh, Philipp von Rosenstiel
First published January 30, 2015, DOI: https://doi.org/10.1212/WNL.0000000000001302
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
978

Share

Article Information

vol. 84 no. 9 872-879
DOI: 
https://doi.org/10.1212/WNL.0000000000001302
PubMed: 
25636714
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 21, 2014
  • Accepted in final form October 13, 2014
  • First Published January 30, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Ludwig Kappos, MD,
    2. Matthias Mehling, MD,
    3. Rafael Arroyo, MD,
    4. Guillermo Izquierdo, MD, PhD,
    5. Krzysztof Selmaj, MD, PhD,
    6. Valentina Curovic-Perisic, BA,
    7. Astrid Keil, MD,
    8. Mahendra Bijarnia, PhD,
    9. Arun Singh, MBBS and
    10. Philipp von Rosenstiel, MD
  1. Ludwig Kappos, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Multiple Sclerosis Journal, (2)Multiple Sclerosis and Related Disorders (3)Journal of Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. all less than 500 USD

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Actelion, (2)Addex,(3)Bayer Health Care,(4)Biogen Idec, (5)Biotica, (6)CSL Behring, (7)Genzyme,(8)Lilly,(9) Merck Serono, (10)Mitsubishi, (11)Novartis,(12)Ono Pharma, (13)Pfizer, (14) Receptos, (15) Roche, (16)Sanofi- aventis, (17)Santhera, (18)Siemens, (19)Teva, (20)UCB, (21)Xenoport I have also lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis. In many cases these talks have been sponsored by non-restricted educational grants from one or another of the above listed companies. Honoraria and other payments for all these activities have been exclusively used for funding of research of my department. Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by non-restricted grants from one or more of these companies.

    Research Support, Government Entities:

    1. Research support by the Swiss National Research Foundation and the European Union

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Swiss MS Society and Novartis and Roche Research Foundations.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Matthias Mehling, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. During the past two years I have received the University of Basel Research Fund.

    Research Support, Foundations and Societies:

    1. During the past two years I was supported by the Swiss Multiple Sclerosis Society.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Rafael Arroyo, MD,
    4. Scientific Advisory Boards:

    1. Teva, Biogen, Novartis, Merck-Serono, Roche, Bayer, Almirall

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Teva, Biogen, Novartis, Merck-Serono, Bayer, Almiral: speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Guillermo Izquierdo, MD, PhD,
    5. Scientific Advisory Boards:

    1. Biogen-Idec, Bayer, Sanofi, Novartis, Merck and Teva.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Sanofi, Merck, Novartis.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Krzysztof Selmaj, MD, PhD,
    6. Scientific Advisory Boards:

    1. Genzyme,BiogenIdec,Novartis,Synthon, Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) financial compensation including travel from Genzyme for presentation at ECTRIMS 2010

    Editorial Boards:

    1. Journal of Neuroimmunology - member of editorial board - 1994 now.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1)Genzyme 2) Novartis 3) BiogenIdec 4) Roche 5)Synthon 6)MerckSerono

    Speakers' Bureaus:

    1. 1) Novartis 2) Merck-Serono 3) BiogenIdec 4) Bayer 5)Genzyme

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Valentina Curovic-Perisic, BA,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am an employee of Novartis Pharmaceuticals Corporation.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Astrid Keil, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Employee of Novartis

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Mahendra Bijarnia, PhD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Novartis Healthcare Pvt. Ltd. Group Leader, Biostatistics & Stats Programming (2008- till date)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Arun Singh, MBBS and
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Novartis Healthcare Private Limited, Expert Scientific Writer, 2011-2014

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Philipp von Rosenstiel, MD
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Until Nov 31, 2014 employed at Novartis Pharam AG, Global Program Medical Director, 5 years Now with Biogen Idec early clinical development

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Salary from Novartis Pharma AG until Nov 31, 2014, from Biogen Idec as of Dec 1, 2014

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the University Hospital Basel (L.K., M.M.), Basel, Switzerland; Hospital Clínico San Carlos (R.A.), Madrid, Spain; Virgen Macarena Hospital (G.I.), Seville, Spain; Medical University of Lodz (K.S.), Lodz, Poland; Novartis Pharmaceuticals Corporation (V.C.-P.), Hanover, NJ; Novartis Pharma AG (A.K., P.v.R.), Basel, Switzerland; and Novartis Healthcare Pvt. Ltd. (M.B., A.S.), Hyderabad, India.
  1. Correspondence to Prof. Kappos: ludwig.kappos{at}usb.ch

Article usage

Article usage: January 2015 to November 2023

AbstractFullPdfSource
Jan 201511607Highwire
Feb 2015654089Highwire
Mar 2015407054112Highwire
Apr 201516301015Highwire
May 2015119811Highwire
Jun 201511284Highwire
Jul 2015871718Highwire
Aug 2015711718Highwire
Sep 201589914Highwire
Oct 20156246Highwire
Nov 201556713Highwire
Dec 20155012Highwire
Jan 20165675Highwire
Feb 20165934Highwire
Mar 20166044Highwire
Apr 20162869Highwire
May 20163056Highwire
Jun 20163674Highwire
Jul 20162422Highwire
Aug 20161765Highwire
Sep 20163356Highwire
Oct 20165723Highwire
Nov 20163400Highwire
Dec 20166813Highwire
Jan 20173593Highwire
Feb 20173833Highwire
Mar 20176325Highwire
Apr 20174333Highwire
May 20174122Highwire
Jun 2017361311Highwire
Jul 20172222Highwire
Aug 201733105Highwire
Sep 20172653Highwire
Oct 20173143Highwire
Nov 20174322Highwire
Dec 20175012Highwire
Jan 20187154Highwire
Feb 201873106Highwire
Mar 20185085Highwire
Apr 2018531112Highwire
May 201851144Highwire
Jun 20187557Highwire
Jul 20184742Highwire
Aug 20184653Highwire
Sep 201810655Highwire
Oct 2018128612Highwire
Nov 201810943Highwire
Dec 201865118Highwire
Jan 20195252Highwire
Feb 20196333Highwire
Mar 201910389Highwire
Apr 201999168Highwire
May 20197771Highwire
Jun 201974113Highwire
Jul 201914821Highwire
Aug 201925221Highwire
Sep 201947043Highwire
Oct 2019396114Highwire
Nov 201927457Highwire
Dec 201930796Highwire
Jan 202021922Highwire
Feb 2020226149Highwire
Mar 2020249119Highwire
Apr 2020213107Highwire
May 202016599Highwire
Jun 2020189612Highwire
Jul 202027098Highwire
Aug 2020347138Highwire
Sep 20201781618Highwire
Oct 20201423220Highwire
Nov 20201692722Highwire
Dec 20201632431Highwire
Jan 20211774337Highwire
Feb 20212464932Highwire
Mar 20211943234Highwire
Apr 20212333931Highwire
May 20212462323Highwire
Jun 20211882614Highwire
Jul 2021158154Highwire
Aug 20211452310Highwire
Sep 20212181715Highwire
Oct 2021208135Highwire
Nov 2021235125Highwire
Dec 202116287Highwire
Jan 20229344Highwire
Feb 20228654Highwire
Mar 202211264Highwire
Apr 20228462Highwire
May 2022921722Highwire
Jun 20225275Highwire
Jul 202210285Highwire
Aug 202258156Highwire
Sep 202239312Highwire
Oct 202253135Highwire
Nov 202259223Highwire
Dec 20223761Highwire
Jan 202365111Highwire
Feb 202336164Highwire
Mar 202369142Highwire
Apr 20235892Highwire
May 20233585Highwire
Jun 20232930Highwire
Jul 20234451Highwire
Aug 20233320Highwire
Sep 20236722Highwire
Oct 2023165102Highwire
Nov 2023296101Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles